Here are four things to know:
1. AxioMed, founded to advance spine technology beyond fusion and first-generation artificial discs, developed a new disc and previously completed its first U.S. investigational device exemption study for the lumbar disc with more than five years of clinical follow-up. Now, the company has produced 60 cervical discs.
2. In addition to producing the cervical discs, AxioMed is raising growth capital to ramp up demand for orders already placed as well as secure additional inventory to immediately expand market share.
3. The raised capital is targeted to qualified private investors with a minimum of $50,000 per investor.
4. AxioMed’s parent company, KICVentures, a private investment company founded by Kingsley R. Chin, MD, aims to bring on “grass roots” investors and encourage more participation.
More articles on orthopedic devices:
Spine device company withdraws $17M IPO: 4 key notes
Orthopedic medical robots market to hit $2.1B by 2025: 4 notes
Medtronic finalizes $1.7B Mazor acquisition—5 key notes on what to expect next
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.